Pulmonary arterial hypertension: A look to the future

Journal of the American College of Cardiology

Volumn 43, Issue 12 SUPPL., 2004, Pages S89-S90

  Rubin, Lewis J ^a,c   Galiè, Nazzareno ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UCSD MEDICAL CENTER   (United States)

Author keywords

BMPR2; bone morphogenetic protein receptor 2; familial pulmonary artery hypertension; FPAH; PAH; PDE5; phosphodiesterase 5; pulmonary arterial hypertension

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; ENDOTHELIN RECEPTOR ANTAGONIST; MONOCROTALINE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PROSTANOID; PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; STATIN; UNCLASSIFIED DRUG; WARFARIN;

CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG MARKETING; DRUG TARGETING; ENDOTHELIUM CELL; GENETIC DISORDER; HUMAN; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER; TREATMENT OUTCOME;

EID: 2942576210     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.02.030     Document Type: Conference Paper

References (20)

1. Deng Z., Morse J.H., Slager S.L., et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Gen. 67:2000;737-744
2. Lane K.B., Machado R.D., Pauciulo M.W., et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet. 26:2000;81-84
3. Thomson J.R., Machado R.D., Pauciulo M.W., et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR2, a receptor member of the TGF-beta family. J Med Genet. 37:2000;741-745
4. Derynck R., Zhang Y.E. TGF-beta-induced signalling pathways. Nature. 425:2003;581-583
5. Christman B.W., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 327:1992;70-75
6. Tuder R.M., Cool C.D., Geraci M.W., et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 159:1999;1925-1932
7. Yuan J.X., Aldinger A.M., Juhaszova M., et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation. 98:1998;400-406
8. Mandegar M., Remillard C.V., Yuan J.X. Ion channels in pulmonary arterial hypertension. Prog Cardiovasc Dis. 45:2002;81-114
9. Eddhaibi S., Humbert M., Fadel E., et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 108:2001;1141-1150
10. Du L., Sullivan C.C., Chu D., et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med. 348:2003;500-509
11. Krick S., Platoshyn O., McDaniel S.S., et al. Augmented K (+) currents and mitochondrial membrane depolarization in pulmonary artery myocyte apoptosis. Am J Physiol Lung Cell Mol Physiol. 281:2001;L887-L894
12. Barst R.J., Rubin L.J., Long W.A., et al. Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 334:1996;296-301
13. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 346:2002;896-903
14. Galie N., Humbert M., Vachiery J.L., et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 39:2002;1496-1502
15. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 347:2002;322-329
16. Petkov V, Mosgeoller W, Ziesche, et al. Vasoactive intestinal polypeptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003;111:1339-46
17. Fanburg B.L., Lee S.L. A new role for an old molecule Serotonin as a mitogen. Am J Physiol. 272:1997;L795-L806
18. Indolfi C., Cioppa A., Stabile E., et al. Effects of hydroxymethylglutaryl coenzyme-A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol. 35:2000;214-221
19. Nishimura T., Faul J.L., Berry G.J., et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med. 166:2002;1403-1408
20. Nishimura T., Vaszar L.T., Faul J.L., et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis in neointimal smooth muscle. Circulation. 108:2003;1640-1645